International Consolidated Companies

What International Consolidated Companies does

Hainan Huluwa Pharmaceutical Group Co., Ltd. (上海证券交易所代码 605199; commonly referenced in the input data as 海南尊龙凯时z6官网首页药业集团股份有限公司) is a China-based, pediatric-focused pharmaceutical manufacturer and distributor, founded in 2008 and listed on the Shanghai Stock Exchange Main Board in 2020. The company develops, produces, and sells children's medicines across both Traditional Chinese Medicine and Western pharmacology categories — including established pediatric SKUs such as Xiaoer Feire Kechuan Keli (小儿肺热咳喘颗粒), the Changyanning (肠炎宁) series, Compound Lysine Granules, and Keke Pian (克咳片). It holds 335 drug approval numbers and 107 patents, has been designated a National Intellectual Property Demonstration Enterprise, and operates manufacturing bases in Hainan, Guangxi, and Zhejiang. The portfolio includes 34 commercialized pediatric drug varieties with 120+ additional products in the R&D pipeline.

The business model is centered on B2B pharmaceutical distribution: the company sells through 26 major pharmaceutical distributors, more than 5,000 retail pharmacies, and 50+ medical institutions, reaching over 2,300 counties and cities across China. Commercial relationships with major pharmacy chains — including Laobaixing, Junyu Pingmin, Wanhe, and Yikang — anchor its retail channel. Beyond drug manufacturing, the company is building an adjacent pediatric digital health layer, including a proprietary AI pediatric diagnostic workbench, a bone age assessment system (claimed 97.2% accuracy), a multimodal pediatric AI system (Shenzhen/神瞳) integrating imaging, genomic, and clinical data, and a Children's Health Big Data Platform. Recent strategic moves include a 2024 partnership with Suzhou Yusen New Drug for innovative TCM development, December 2024 Customs AEO Advanced Certification (signaling internationalization intent), and an earlier acquisition of Guangxi Weiwei Pharmaceutical (2015).

Name

International Consolidated Companies

Legal name

海南尊龙凯时z6官网首页药业集团股份有限公司

Website

https://iccina.com

Company type

Public

Founded year

2008

Operating status

Operating

Headcount range

1–10 employees

Short description

China-based pediatric-focused pharmaceutical manufacturer (Shanghai Stock Exchange: 605199) producing children's TCM and Western medicines, distributing through 5,000+ pharmacies across 2,300+ counties, with a growing AI pediatric diagnostic platform.

Ownership category

akta.pro rank

Product category

Pediatric Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Pediatric OTC Medicines (HLAIADAL)

akta.pro secondary industries

Specialty Care Pharmaceuticals (HLAIAAAB), Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges) (CRADAMAD), Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO)

Keywords

• Pediatric pharmaceuticals
• Children's medication
• Traditional Chinese medicine
• Pharmaceutical manufacturing
• Drug distribution

Headquarters

HQ city

Sarasota

HQ country

United States

HQ region

North America

Offices6 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Marketing or Sales, Personnel, Infrastructure

Revenue model

1. 药品生产与销售: 主要通过生产销售儿童药及大健康产品获利，涵盖儿科、妇科、抗生素、呼吸系统、消化系统、心脑血管及滋补类药物
2. 产品线覆盖: 34个在产在销的儿童药品种，主打产品包括小儿肺热咳喘颗粒、肠炎宁系列、复方赖氨酸颗粒等，在研产品约120个

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

International Consolidated Companies (legal name: Hainan Huluwa Pharmaceutical Group Co., Ltd.) is a pharmaceutical group focused on the R&D, manufacturing, and distribution of pediatric medicines. Its product portfolio spans seven therapeutic categories including pediatric respiratory, gastrointestinal, nutritional, antibiotics, gynecological, cardiovascular, and tonic medications, with approximately 34 commercialized pediatric drug varieties and around 120 products in R&D. The company distributes through its own subsidiaries, 26 pharmaceutical distribution partners, 30+ chain pharmacy groups, 650 medical institutions, and 5,000+ retail outlets across China.

Product overview

International Consolidated Companies (尊龙凯时z6官网首页药业集团) operates as a pharmaceutical group focused on pediatric medicines, structured as a multi-subsidiary operation with product development, manufacturing, and marketing divisions. The portfolio centers on the '小儿肺热咳喘颗粒' as the flagship respiratory product, complemented by the '肠炎宁系列' for gastrointestinal applications and '复方赖氨酸颗粒' for nutritional support. The company also produces antibiotics, gynecological, cardiovascular, and tonic medications across seven major categories, with approximately 34 commercialized pediatric drug varieties and around 120 products in the R&D pipeline. Key sub-brands include '新费乐' for premium pediatric formulations and '葫芦世家' for Zhejiang regional distribution. The company supplements its pharmaceutical offerings with AI-driven technology platforms — a children's health big data platform supporting R&D decisions, and an AI pediatric intelligent workbench providing multi-modal diagnostic assistance — reflecting a platform-plus-intelligent-tools model that bridges pharmaceutical manufacturing with digital health capabilities.

Differentiator

Problem solved

Functional benefit

Brands

• 新费乐 (Xin Fei Le): Children's medication brand featuring Xiaoer Feire Kechuan Granules (小儿肺热咳喘颗粒)
• 葫芦世家 (Hulu Family)

Products and services

• Xiaoer Feire Kechuan Keli (小儿肺热咳喘颗粒)
• Changyanning Series (肠炎宁系列)
• Compound Lysine Granules (复方赖氨酸颗粒)
• Keke Pian (克咳片)
• Xiaoyan Ling (消炎灵)
• Xin Feile Pediatric Formulations (新费乐)
• Hulu Jia Shi (葫芦世家) Distribution Brand

Quantifiable outcome

• 中国医药工业百强中药企业排名第40位
• +2 more outcomes

Named customers4 records

Segments2 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature4 records

Partnerships

Ten partnerships are on record, tiered 核心.

• 苏州玉森新药核心Strategic or Co-development Partner · 1 July 2024尊龙凯时z6官网首页与苏州玉森新药达成战略合作，双方将携手推进中药创新药的现代化进程，为新药研发注入新动力。
• 盈科瑞核心Strategic or Co-development Partner · 1 January 2022公司与盈科瑞携手，共同致力于新制剂与经典名方的研发工作，以推动儿童健康领域的进步。
• 1药网核心Strategic or Co-development Partner · 1 January 2020尊龙凯时z6官网首页与1药网达成合作，共同探索在互联网与医药健康融合领域的新机遇。
• 老百姓大药房核心Channel Partner/ Reseller/ Distributor尊龙凯时z6官网首页集团与老百姓大药房的战略合作现已启动，旨在为儿童健康提供更高端的产品与服务。
• 漱玉平民大药房核心Channel Partner/ Reseller/ Distributor尊龙凯时z6官网首页与山东漱玉平民大药房达成了战略合作，双方将共同致力于提升儿童药在零售终端的可及性与服务。
• 万和药房连锁核心Channel Partner/ Reseller/ Distributor尊龙凯时z6官网首页集团已与重庆万和药房连锁达成战略合作，双方将共同致力于提升儿童健康服务水平。
• 怡康医药核心Channel Partner/ Reseller/ Distributor尊龙凯时z6官网首页与陕西怡康医药签署了战略合作协议，双方将整合资源，共同推动儿童药在区域市场的健康发展。
• 中国药店核心GTM or Marketing Partner尊龙凯时z6官网首页与中国药店签署了关于金牌儿药师项目的战略合作协议，旨在共同提升儿童用药的全方位服务水平。
• 中国中药协会儿童健康与药物研究卓越委员会核心Strategic or Co-development Partner担任世界中医药学会联合会儿科卓越委员会以及中国民族医药学会儿科分会的副会长单位。
• 儿童药物研发与产业化联盟核心Strategic or Co-development Partner公司加入儿童药物研发与产业化联盟，与业界伙伴共同致力于推动中国儿童用药领域的进步与高质量发展。

Scale indicators11 records

Recent moves12 records

Expansion highlights5 records

Broad incumbents

• 江中药业 (Jiangzhong Pharmaceutical): Mid-cap A-share listed TCM and OTC manufacturer with subsidiary focus on pediatric nutrition/health (江中牌小儿健胃消食片); similar size, listing status, and product adjacency.
• 仁和药业 (Renhe Pharmaceutical): OTC and TCM player with deep pharmacy distribution in China (妇炎洁, 优卡丹, 可立克); directly comparable A-share peer with overlapping OTC pediatric positioning and similar channel strategies.
• 太极集团 (Taiji Group): Large diversified TCM and pharmaceutical group with broad pediatric and adult categories (急支糖浆, 藿香正气); comparable manufacturer-distributor model across China with significantly larger scale.
• 华润三九 (CR Sanjiu): State-backed dominant OTC and TCM incumbent (999 brand family) with a pediatric line that overlaps Huluwa's categories; broader scale and portfolio but less specialized in pediatric-only franchises.
• 以岭药业 (Yiling Pharmaceutical): Innovation-driven TCM manufacturer (连花清瘟, 通心络) operating pediatric respiratory products; comparable in TCM modernization and hospital channel but with a broader therapeutic footprint.

Direct peers

• 健民集团 (Jianmin Pharmaceutical Group): Wuhan-headquartered TCM and pediatric pharmaceutical manufacturer with strong brand recognition (龙牡壮骨颗粒), competing head-on with Huluwa in the pediatric TCM specialty retail channel.
• 亚宝药业 (Yabao Pharmaceutical): Pediatric pharmaceutical specialist with major respiratory and CNS products for children (小儿氨酚烷胺颗粒), comparable A-share listed mid-cap operating in the same pediatric OTC and prescription categories as Huluwa.
• 济川药业 (Jichuan Pharmaceutical): Leading pediatric respiratory and GI pharma in China (蒲地蓝消炎口服液, 小儿豉翘清热颗粒), with extensive hospital and pharmacy distribution; directly comparable business model centered on branded pediatric specialty products.
• 葵花药业 (Sunflower Pharmaceutical Group): One of China's largest dedicated pediatric pharmaceutical groups, with brand franchises (小儿氨酚黄那敏, 小儿肺热咳喘) overlapping directly with Huluwa's flagship respiratory and OTC categories. Closest direct competitor in the Chinese pediatric OTC/TCM segment.

Emerging players

• 一品红药业 (Apeloa / Yipinhong Pharmaceutical): A-share listed mid-cap pediatric-focused pharma manufacturer with comparable pediatric specialty pipeline and channel structure; partial overlap in pediatric respiratory and GI therapeutics, though with a smaller commercial footprint.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance11 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about International Consolidated Companies